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Objectives: The objective of the study is to determine cardiac autonomic control in patients undergoing as-
sessment for and/or LVAD therapy.
Methods: Heart rate variability (HRV) was measured in 17 explanted LVAD, 17 implanted LVAD and 23 NYHA
III–IV classiﬁed chronic heart failure (CHF) patients and ten healthy matched controls under three condi-
tions: supine free breathing, standing and supine controlled breathing. Five measures of HRV were assessed:
mean R–R interval (mR–R), high frequency (HF) and low frequency (LF) spectral power, LF in normalised
units (LFnu), and LF to HF (LF:HF) ratio.
Results: Repeat measures ANOVA showed signiﬁcant (p b 0.05) differences in HRV between all three condi-
tions within groups. Lower values were observed in CHF for LF(in log natural units) compared with explanted
patients (−1.4 [95% CI−2.6 to−0.7], p = 0.04) and controls (−2.1 [−3.5 to−0.7], p = 0.001) and for LF:
HF compared with implanted patients under paced breathing conditions (z = −2.7, p = 0.007) and controls
in standing (z = −2.9, p = 0.004) and paced breathing conditions (z = −2.3, p = 0.02). However, no sig-
niﬁcant differences were seen between explanted, implanted and control groups under any condition.
Conclusions: Patients implanted with an LVAD and explanted from a LVAD following myocardial recovery
demonstrate a more normal dynamic response to autonomic stimuli and have a lower HRV risk proﬁle com-
pared to CHF patients.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Chronic heart failure (CHF) is a complex, multifactorial syndrome
characterised by: inadequate tissue perfusion, ﬂuid retention, skeletal
muscle abnormalities, progressive activation of the neuroendocrine sys-
tem (e.g. RAAS) and inappropriate immune response [1]. CHF patients
demonstrate severe derangement of the autonomic nervous system
(ANS) [2,3] characterised by chronic sympathetic hyperactivation [2],
vagal withdrawal [3], resetting of the baroreﬂex sensitivity [4] and de-
creased peripheral and central responsiveness to adrenergic input [5].
This chronic sympathetic activation manifests as greatly altered
heart rate variability (HRV). Overall R–R interval variation is lower
in CHF patients who die compared with survivors [6–8]. Spectralre Health Sciences, University
, UK. Tel.: +44 1865 617938;
n).
Ltd. All rights reserved.
diovascular autonomic contro
13), http://dx.doi.org/10.1016analysis of HRV produces a characteristic HRV proﬁle in CHF with at-
tenuated variability both in the low frequency (LF, 0.04–0.15 Hz) and
reduced low-to-high frequency ratio (LF:HF) which both predict pa-
tient mortality [9,10].
Historically, the only cure for end stage CHF has been transplanta-
tion. In post-transplant patients, there is some restoration in auto-
nomic modulation of the native sinus node. While there is also
some evidence for partial (sympathetic) reinnervation of the donor
heart, autonomic control and HRV remain well below normal levels
[11].
Using left ventricular assisting devices (LVADs) to bridge patients
to transplantation, destination therapy [12], or recovery [13] has be-
come successful practise [14]. In combination with optimal pharma-
cotherapy, our group has been able to reverse many of the
pathological changes associated with end stage heart failure and up
to two thirds of patients with dilated cardiomyopathy can be
explanted [15]. These patients may avoid transplantation and tend
to lead higher quality lives than transplant patients [16].l in patients undergoing left ventricular assist device (LVAD) support
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death for CHF patients [17] due to autonomic dysfunction and poor
innervations respectively. While cardiac function and exercise capac-
ity [18] of explanted LVAD patients exceed that of CHF sufferers, it re-
mains unknown whether the same is true for cardiac autonomic
function.
The aim of the present study was to assess the impact of ‘bridging
to recovery’ on autonomic function in patients diagnosed with end
stage heart failure undergoing assessment for and/or LVAD support
therapy.
2. Methods
2.1. Patients
Heart rate variability was assessed in an opportunity sample of 17 explanted LVAD
patients (age 36 ± 11 years, 12 men), 17 currently implanted patients (33 ± 10 years,
16 men), 23 NHYA III–IV classiﬁed chronic heart failure (CHF) patients (42 ± 12 years,
13 men) and ten healthy, age- and sex-matched controls from hospital and university
staff (37 ± 12 years, 8 men). Assessments took place over the period of January 2004 to
July 2008, therefore LVAD previously implanted in the explanted patients consisted of: a
HeartMate 1 (n = 8); a HeartMate 2 (n = 5) (Thoratec Corporation, Pleasanton, CA,
USA) a Levitronix (n = 1) (Thoratec Corporation, Pleasanton, CA, USA), a Heartware
(n = 1) (Heartware, Miami, USA) or a Jarvik 2000 (Jarvik Heart Inc. NY, USA, n = 2).
All patients had been implanted only once but one had received additional right ventric-
ular assistance from a Thoratec VAD (Thoratec Corporation, Pleasanton, CA, USA). In
twelve explanted patients, the original diagnosis was idiopathic dilated cardiomyopathy
(IDCM), in four it was peripartum cardiomyopathy and one had myocarditis.
Currently implanted LVAD patients had: a HeartMate 1 (n = 4); a HeartMate 2
(n = 7); a Heartware (n = 1); a Jarvik 2000 (n = 3), or a Thoratec (n = 2). Twelve
patients had IDCM, one peripartum cardiomyopathy, three ischaemic heart disease
(IHD), and one had myocarditis.
Of the CHF patients, 11 were diagnosed with IDCM, four with peripartum cardio-
myopathy, six with IHD and two had myocarditis. Further anthropometric, physiolog-
ical and pharmacological data are displayed in Table 1.
The control group was matched for age and sex with the explanted LVAD patient
group. All controls were either sedentary or moderately physically active. None had a
history of cardioneuroregulatory disorders. None were taking any prescribed medica-
tions, with the exception of oral contraceptives, at the time of testing. Due to the
oligomenorrhoaeic nature of the female CHF patients, menstrual cycle phase was not
controlled for in this group or their matched controls.
The local NHS ethics committee approved the research protocol and informed con-
sent was obtained from all participants. The investigation conforms with the principles
outlined in the Declaration of Helsinki.Table 1
Descriptive characteristics of implanted and explanted LVAD patients.
CHF
N 23
Males/females 13/10
Age (years) 42.3 ± 12.1
Mass (kg) 82.1 ± 19.5
Stature (cm) 168.6 ± 11.4
BMI (m2·kg) 29.0 ± 7.7
BSA (m2) 1.93 ± 0.48
Time from explant/implant/diagnosis (days) 1291 ± 1577
NYHA class 3.3 ± 0.7
LVEF at time of test (%) 39.5 ± 14.2
Aetiology (number)
IDCM 11
IHD 5
MYO 3
PP 4
Clenbuterol treatment (%) 0
Clenbuterol at time of test (%) 0
Digitalis (%) 27
β-Blockers (%) 64
ACE-inhibitors (%) 27
ARB (%) 58
Spirolactolone (%) 41
Other (%) 60
BMI—body mass index, BSA—body surface area, EF—ejection fraction, IDCM—idopathic dilate
heart failure, ACE—angiotensin converting enzyme, ARB—angiotensin receptor blocker. All pha
HRV measurement except clenbuterol treatment — refers to whether the patient had ever rec
Please cite this article as: Nunan D, et al, Cardiovascular autonomic contro
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Two lead ECGs were recorded using a TF5 heart rate variability analysis system
(Advanced Medical Diagnostics Ltd., Leeds, UK). This is a commercially available unit,
which is mobile as well as being relatively simple and quick to ﬁt to patients. The hard-
ware and software components of the TF5 and its comparative validity with a 12 lead
ECGs have been described previously [19]. The TF5 HRV analysis software was used to
analyse the R–R interval data via fast Fourier transformation. All recording and analysis
protocols surpass the criteria for sampling rates, conversion rates and mathematical
treatment of data for HRV analysis [20].
2.3. Protocol
After ﬁtting the patients with the TF5 chest strap in accordance with manufac-
turers' instructions, patients were allowed resting supine for 5-min. After this time,
5-min ECGs were recorded in three conditions: supine with free breathing, standing
and supine with controlled breathing at 12 breaths·min−1. The supine condition was
used as a baseline measure of resting autonomic modulation. The standing condition
was used to represent orthostatic challenge, known to evoke sympathetic responses
in healthy subjects. Finally the controlled breathing condition was used to stimulate
vagal modulation of the SA node. We have reported the validity and reliability of this
testing protocol in healthy participants previously [19]. All R–R interval data were
ﬁrst ﬁltered using the automated algorithms available in the software. Additional man-
ual ECG analysis, non-sinus beat rejection and consequent interpolation were also
performed by a highly experienced HRV researcher.
All HRV measures recommended for use during short-term data collection were
calculated [20]. In the frequency domain: high frequency spectral power (HF, 0.15–
0.40 Hz), low frequency spectral power (LF 0.04–0.15 Hz) normalised low and high
frequency spectral power (LFnu, HFnu), and the ratio of low to high frequency spectral
power (LF:HF). In the time domain: mean R–R interval, standard deviation or
normal-to-normal intervals (SDNN) and the root mean square of successive interval
differences (rMSSD) were measured.
2.4. Statistical analysis
Two-way mixed (group by position) analysis of variance was used to determine
whether differences between conditions (i.e. position and breathing) and between con-
trol, CHF, implanted and explanted patients (group) existed. Analysis was carried out on
HRV measures representative of vagal modulation (HF), mixed sympathovagal and baro-
reﬂex activity (LF) and its normalised units (LFnu), sympathovagal interaction (LF:HF)
and mean R–R interval. Due to heterogeneous variances and non-normal distributions
which could not bemodiﬁed successfully by transformation, LF:HFwas analysed using re-
peated nonparametric Kruskal–Wallis tests (n = 3) with post-hoc Mann–Whitney U
tests. For all tests, a two-sided value of p b 0.05 was considered statistically signiﬁcant.
We present data as mean ± SD and the 95% conﬁdence interval/limits (CI) for the
mean to demonstrate the magnitude of effects across each of the groups.Implanted Explanted Control
17 17 10
16/1 12/5 8/2
32.8 ± 10.2 36.2 ± 10.9 37.0 ± 12.2
78.7 ± 19.4 86.7 ± 24.9 87.2 ± 13.0
180.4 ± 8.5 176.1 ± 12.0 178.2 ± 11.4
24.0 ± 4.8 27.6 ± 5.7 27.3 ± 1.7
1.98 ± 0.55 2.18 ± 0.70 2.17 ± 0.43
184 ± 136 718 ± 639 n/a
1.8 ± 0.7 1.1 ± 0.3 n/a
47.8 ± 9.4 62.6 ± 13.3 n/a
12 12 n/a
3 0 n/a
1 1 n/a
1 4 n/a
25 100 n/a
6 0 n/a
38 100 n/a
87 87 n/a
62 100 n/a
62 87 n/a
50 62 n/a
87 38 n/a
d cardiac myopathy, IHD—ischaemic heart disease, MYO—myocarditis, PP—post-prandial
rmacolgical data refer to whether patients were prescribed with the drug type at time of
eived clenbuterol; n/a—non-applicable.
l in patients undergoing left ventricular assist device (LVAD) support
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of signiﬁcant short-term HRV risk factors reported previously [9,10] with values
obtained for explanted, implanted and CHF patients and for comparison, control sub-
jects. This analysis allowed visual evaluation of spectral HRV proﬁles at different points
during ‘bridging to recovery’ in comparison with heart failure patients and healthy
control individuals.
3. Results
Table 1 provides the descriptive characteristics of the implanted,
explanted and CHF patient groups. Implanted and explanted patients
were similar in terms of age and anthropometric measures, disease
aetiology, and geometric echocardiographic measures. The CHF pa-
tients were older and some differences in pharmacotherapy existed
between groups, particularly in the frequency of use of clenbuterol.
3.1. Comparisons between patient groups and healthy controls
Table 2 shows the changes in R–R interval, HF power as natural
logarithm (ln ms2), LF(ln) and LF:HF under supine, standing and su-
pine controlled breathing conditions in implanted, explanted and
CHF patients and healthy controls.
Repeated measures ANOVA showed signiﬁcant (p b 0.05) differ-
ences for all three conditions within groups. There were signiﬁcant
group differences across conditions for LF in log transformed
(LF(ln), p = 0.02) and normalised units (LFnu, p = 0.01) and for
LF:HF (p = 0.007) in the paced breathing condition only. There
were no signiﬁcant between group differences in R–R interval
(p = 0.08) or HF(ln) (p = 0.13). Post-hoc analyses demonstrated
that nearly all group differences were between the CHF patients
and one or more of the remaining three groups as follows: signiﬁ-
cantly lower values for LF(ln) compared with explanted patients
(−1.4 [95% CI −2.6 to −0.7], p = 0.04) and controls (−2.1 [−3.5
to −0.7], p = 0.001); for LFnu compared with implanted (−19.4
[−38.1 to −0.5], p = 0.04) and controls (−20.3 [−38.6 to −1.9],
p = 0.03); and for LF:HF compared with implanted patients under
paced breathing conditions (z = −2.7, p = 0.007) and controls in
standing (z = −2.9, p = 0.004) and paced breathing conditions
(z = −2.3, p = 0.02).
Due to the relatively small number of patients available, a visual
analysis of changes in LF:HF ratio due to standing and controlled
breathing was also performed. Fig. 1 shows the expected increase in
LF:HF due to standing compared with values measured in the supineTable 2
Vales for mean R–R interval, high frequency (HF) and low frequency (LF) spectral power a
explanted LVAD patients.
Heart failure Implanted
Measures obtained supine
mR–R(ms) 911 ± 334 (686 to 1135) 804 ± 132 (702 to 90
LF(ln) 4.2 ± 1.7 (3.0 to 5.4) 5.0 ± 1.4 (3.9 to 6.0
HF(ln) 4.1 ± 2.1 (2.7 to 5.5) 4.2 ± 1.4 (3.1 to 5.3
LF(nu) 52 ± 23 (37 to 68) 68 ± 12 (59 to 77)
LF:HF 1.8 ± 1.9 (0.6 to 3.1) 3.2 ± 3.2 (0.6 to 5.5
Measures obtained standing
mR–R(ms) 759 ± 145 (662 to 857) 694 ± 82 (631 to 75
LF(ln) 3.8 ± 1.1 (3.1 to 4.6) 4.8 ± 1.4 (3.7 to 5.8
HF(ln) 3.5 ± 1.9 (2.3 to 4.8) 3.7 ± 1.5 (2.6 to 4.9
LF(nu) 56 ± 25 (39 to 73) 74 ± 20 (58 to 89)
LF:HF 2.5 ± 2.7 (0.7 to 4.3) 5.3 ± 5.2 (1.3 to 9.3
Measures obtained supine with controlled breathing
mR–R(ms) 858 ± 210 (717 to 999) 770 ± 121 (677 to 86
LF(ln) 3.6 ± 1.6 (2.5 to 4.7) 4.8 ± 1.2 (3.9 to 5.7
HF(ln) 4.5 ± 2.4 (2.9 to 6.1) 4.6 ± 1.5 (3.4 to 5.7
LF(nu) 32 ± 25 (15 to 49) 56 ± 21 (40 to 72)
LF:HF 0.7 ± 1.1 (0.0 to 1.9) 1.4 ± 1.2 (0.8 to 2.9
All data are mean ± standard deviation with 95% CI for the mean in parentheses; ms — mi
at12 breaths•min−1.
Please cite this article as: Nunan D, et al, Cardiovascular autonomic contro
and pharmacologic therapy, Int J Cardiol (2013), http://dx.doi.org/10.1016position in control, heart failure and implanted and explanted pa-
tients. The pattern of change was similar in both implanted and
explanted patients and their values were more closely matched to
those of the control group compared to those of CHF patients.
4. Discussion
The aim of this study was to examine the potential of LVAD
unloading and optimal pharmacotherapy to alter cardiac autonomic
nervous system activity in end-stage heart failure patients, a condi-
tion typically characterised by severe autonomic derangement. In
explanted patients, our power-spectral analysis of HRV demonstrated
patterns of cardiac ANS activity that were similar to those of healthy,
age-matched controls.
Successful explantation is the desired clinical endpoint for LVAD
patients who are ‘bridged to recovery’ [13,14] and although not all
patients achieve this some degree of reverse modelling occurs in
most [21]. The present data show that in currently implanted LVAD
patients, there appears to be a partial normalisation of the HRV proﬁle
as we found no difference between controls and implanted patients
for mean R–R interval or spectral HRV values.
4.1. Low frequency spectral power: explants and implants
The characteristic HRV proﬁle of heart failure patients shows severe-
ly attenuated overall variability, particularly in the low frequency spec-
tral component (LF, 0.04–0.15 Hz). Values for LF predictive of mortality
range from 3.3 ln ms2 from Holter recordings [22] to between b13 ms2
[9] and 20 ms2 [10]when extracted frommore-stationary recordings as
in the present study. We have previously calculated estimated normal
values for the LF frequency component to be around 519 ± 219 ms2
or 5.0 ± 1.8 ln ms2 [23]. HRV measures should be compared only be-
tween comparable R–R interval recording conditions and the following
discussion relates to data collected supine with free breathing.
Mean LF power in our controls was within the normal range. Re-
markably however, and despite having been previously diagnosed
with end-stage heart failure, mean LF values of explanted patients
were similar to that of controls and therefore population norms. Per-
haps more importantly, both mean and the lower 95% CI (4.7 [3.7 to
5.8]) values were well in excess of values known to predict mortality
in CHF. While we do not have longitudinal data to describe the changes
in HRV from pre-implantation to explantation, it is clear that LF powernd LF:HF ratio under three conditions in healthy controls, heart failure, implanted and
Explanted Control
5) 890 ± 104 (827 to 953) 947 ± 123 (858 to 1035)
) 5.6 ± 1.5 (4.6 to 6.5) 6.3 ± 1.6 (5.3 to 7.2)
) 5.4 ± 0.9 (4.8 to 5.9) 5.5 ± 1.3 (4.6 to 6.4)
53 ± 26 (38 to 69) 66 ± 17 (53 to 78)
) 2.6 ± 3.5 (0.4 to 4.9) 3.4 ± 3.6 (0.6 to 6.0)
7) 766 ± 78 (719 to 813) 795 ± 81 (737 to 853)
) 4.7 ± 1.2 (4.0 to 5.4) 6.0 ± 1.2 (5.2 to 6.9)
) 3.7 ± 1.1 (3.0 to 4.3) 4.2 ± 1.4 (3.2 to 5.2)
74 ± 17 (64 to 84) 85 ± 5 (81 to 89)
) 4.9 ± 4.9 (1.6 to 7.8) 7.0 ± 5.6 (3.1 to 11.4)
2) 890 ± 97 (832 to 949) 978 ± 113 (898 to 1059)
) 5.4 ± 1.5 (4.5 to 6.3) 5.6 ± 1.3 (4.7 to 6.5)
) 6.1 ± 1.4 (5.4 to 7.0) 5.6 ± 1.2 (4.7 to 6.5)
35 ± 24 (21 to 50) 50 ± 23 (33 to 66)
) 0.8 ± 0.9 (0.3 to 1.4) 1.6 ± 1.5 (0.4 to 2.7)
lliseconds; nu — normalised units; ln — log units; controlled breathing was performed
l in patients undergoing left ventricular assist device (LVAD) support
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Fig. 1. LF:HF ratio values in LVAD implanted, LVAD explanted and chronic heart failure
patients and controls.
4 D. Nunan et al. / International Journal of Cardiology xxx (2013) xxx–xxxof both explanted and currently implanted patients is much more sim-
ilar to normal values than to the heart failure patients measured here.
Explanted and currently implanted LVADpatients therefore demonstrate
a lower HRV risk proﬁle compared with chronic heart failure patients. If
we assume that implanted and explanted patients' LF valueswere similar
to those of the heart failure group prior to LVAD therapy, their current,
near-normal levels demonstrate the potential for autonomic recovery
following our treatment programme.
4.2. Low to high frequency ratio: explants and implants
We analysed the ratio of low to high frequency powers (LF:HF)
ratio to evaluate the interaction between both ANS branches. It
should, however, be noted that the conditions under which the be-
haviour of LF:HF actually matche sympathetic activation and/or
vagal withdrawal are somewhat limited [24]. Interpretation of LF:HF
in patients demonstrating severe autonomic derangement is particu-
larly problematic [2,3]. Whereas in healthy populations LF:HF usually
reﬂects an increase in sympathetic outﬂow (and/or vagal withdraw-
al) values in LF:HF and in CHF patients with excessive sympathetic
outﬂow is, paradoxically, very low. This is because of very low values
for LF due to severely attenuated baroreﬂex sensitivity in these pa-
tients [25]. Regardless of its physiological meaning, low LF:HF is a
risk factor of mortality and cardiac event in CHF patients [9,10]. The
reduced LF component in the HRV proﬁle of CHF patients results in
a low LF:HF ratio and the most sensitive values to predict mortality
reported by La Rovere et al. were b0.37 and b0.43 [9].
In the present study, values for LF:HF were much higher and almost
identical in explants, implants and controls. LF:HF showed great
intra-individual variation and while the lower 95% CI in explants was
below the cut-point of La Rovere et al. [9], this was not the case in im-
planted patients and the mean values in both cases do not suggest that
these patients are at signiﬁcantly heightened risk of SCD [10]. From
these data, we propose that the balance between LF and HF power is
likely to be partially restored in CHF patients during LVAD support and
that this restoration of balance is maintained post-explantation.
4.3. Autonomic response to standing and controlled breathing
The response of HRV measures to orthostatic challenge and deep
breathing has not been used in prognosis in CHF patients, however it re-
mains a useful tool bywhich to assess dynamic control of ANS. Typically,Please cite this article as: Nunan D, et al, Cardiovascular autonomic contro
and pharmacologic therapy, Int J Cardiol (2013), http://dx.doi.org/10.1016this is deranged in CHF patients and we aimed to determine whether a
normal proﬁle of change in HRV measures had returned in LVAD pa-
tients. Standing comprises an orthostatic challenge, the autonomic re-
sponse to which is typiﬁed by a reproducible decreased HF and
increased LF contribution to total spectral power [26]. The use of con-
trolled breathing typically increases the vagal contribution to SA node
control [27]. CHF patients with sympathetic hyperactivity tend to
show blunted decreases in vagal indices (HF, HFnu) and increases in in-
dices (LFnu) of sympathetic activation [26]. While this was the case in
our CHF patients, the LF:HF for implanted and explanted patients
displayed a typical response to standing (increase) and decreased
under the increased vagal outﬂow created by controlled breathing
(Fig. 1). Even the magnitudes of these changes were highly similar be-
tween groups the increase in LF:HF upon standing demonstrates com-
bined vagal withdrawal and sympathetic activation (increased relative
LF contribution) mediated via the baroreﬂex. These are the ﬁrst data,
therefore, to demonstrate a normalisation of HRV indices recorded
under resting conditions that indicate a reduced likelihood of cardiac
events in currently implanted and explanted LVAD recipients. These
data are also the ﬁrst to demonstrate normality of the dynamic auto-
nomic responses to simple sympathetic and vagal perturbations.
4.4. Potential mechanisms of recovery
The unloading of the failing myocardium by LVAD implantation,
combined with optimal pharmacotherapeutic interventions results in
multiple favourable physiological changes including partial restoration
of hemodynamic responses to exercise[18], ‘reverse remodelling’[28] of
themyocardiumwhichhas beenwell described at bothmacrostructural
[29] and cellular levels [30]. Burkhoff et al. [29] suggest restoration of
the ‘normal neurohormonal milieu’ is a precursor to such adaptations
but descriptions of this autonomic normalisation are scarce. Scintigra-
phy demonstrates that hemodynamic improvements are accompanied
by improved sympathetic innervation of failing myocardium in im-
planted patients [31]. Changes in sympathetic innervation correlate im-
provements in clinical measures including B-type natriuretic peptide
and pulmonary systolic pressure [32]. LVAD implantation may increase
myocardial noradrenalin via the renin–angiotensin–aldosterone path-
way [30] but the optimised pharmacotherapy [15] in these patients re-
duces or negates this change. No group has yet published data
describing changes in integrated cANS function (sympathovagal inter-
action) associated with LVAD therapy.
In addition to being a signiﬁcant prognostic marker, HRV provide
at least some information regarding the overall functioning of the
cANS. The near-normal resting HRV index values observed in im-
planted and explanted patients suggest a degree of autonomic
normalisation. It appears that by unloading the left ventricle, the
cycle of sympathetic over activity is corrected to a signiﬁcant degree.
These data show that LVAD therapy potentially restores predictable
responses and near normal values for reﬂex cardiac autonomic activ-
ity in the cANS of what were once most-likely severely deranged sys-
tems of patients with end stage heart failure.
5. Limitations
We acknowledge that the major limitation of this study is the
cross-sectional design. During the study period, only one patient with
end-stage heart failure was implanted then explanted from LVAD.
Moreover, only twopatientsmoved from implanted to explanted states.
The duration of a study required to collect longitudinal data would ap-
pear to be more than several years. Of note is that the thirty-seven pa-
tients in the present study represent a very large proportion of
survivors of LVAD implantation (and explantation) over a period of ap-
proximately ﬁve years. In fact, they represented the entire ongoing
LVAD implant population from our hospital that at the time of the
study were in sinus rhythm and/or not paced. In turn, they alsol in patients undergoing left ventricular assist device (LVAD) support
/j.ijcard.2013.07.075
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three patientswere not able to haveHRVmeasured. In one case thiswas
due to persistent atrial ﬁbrillation and two other cases due to the use of
implantable pacing devices.
We recommended that a longitudinal study, tracking changes in
HRV and possibly baroreﬂex gain or other sympathetic measurement
be carried out to determine if LVAD therapy can lead to deﬁnite auto-
nomic recovery in successfully treated patients. A single-centre pro-
spective study may be prohibitively long or may have very small
subject numbers. Such data collection would no doubt be made easier
by collaboration and co-operation between units in order to combine
their experience and data to provide a better overall understanding of
the outcomes from this rare but seemingly very successful intervention.
6. Conclusions
Patients implanted with and explanted from a LVAD following
myocardial recovery demonstrate a lower HRV risk proﬁle compared
to patients with end-stage heart failure and have a dynamic response
to autonomic stimuli similar to healthy matched controls.
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